Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the ...

Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

Olympus has inked a collaboration deal for the global distribut | Olympus inked a collaboration deal for the global ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Roche’s Foundation Medicine has linked with Fulgent Genetics to offer a new diagnostic test that identifies a person’s ...

A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to ...

A cross-section of biotech leaders is launching the American Biotech Innovation Alliance (ABIA) with the goal of uniting ...

Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...